ArticleCerebellum (London, England)2026
Clinical Heterogeneity in a Scandinavian FMR1 Premutation Carrier Cohort and Basal Ganglia Atrophy in FXTAS.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological CGG expansions in the FMR1 gene, encompassing premutations (55–200 repeats) and full range mutations (> 200 repeats), cause a spectrum of complex and incurable disorders. Premutation carriers (PMC), particularly men, face the risk of developing fragile X-associated tremor/ataxia syndrome (FXTAS). Other conditions associated with premutations in FMR1 include both Fragile X-associated primary ovarian insufficiency (FXPOI), and Fragile X-associated neuropsychiatric disorders (FXAND). Hyperintensities in the middle cerebellar peduncle (MCP), known as the MCP sign, have been considered a radiological hallmark for FXTAS. FMR1-related disorders have not been characterized in Scandinavia. Here, we delineate the clinical spectrum of FMR1 related disorders among PMC emphasizing neuroimaging abnormalities and assess the correlation between CGG repeat size and clinical parameters as well as neuroimaging abnormalities at a tertiary center in Sweden. In total 33 PMC were evaluated (19 women and 14 men) of which 21 received a FMR1 related disorder (64%). As expected, penetrance for a FMR1 related disorder was higher among men (11/14 [79%]) than in women (12/19, [63%]). We also found that hyperintensities in the splenium of corpus callosum (CCS sign) were more prevalent than the MCP sign, and volumetric analyses revealed atrophy in the basal ganglia, cerebellar grey and white matter among FXTAS patients. CGG expansion size correlated with motor scores but not with age of onset. Our findings indicate a high prevalence of FMR1-related disorders in this PMC cohort in which the CCS sign is more common than the MCP sign. Larger cohort studies are necessary to assess atrophy of the basal ganglia and its clinical correlations among FMR1 PMC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.